<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02485041</url>
  </required_header>
  <id_info>
    <org_study_id>SID123_DDI_I_2014</org_study_id>
    <nct_id>NCT02485041</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg</brief_title>
  <official_title>An Open Label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetic Interaction of Dapoxetine 30 mg and Mirodenafil 100 mg in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Chemicals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Healthy male volunteers were administered alone and in combination with dapoxetine 30mg&#xD;
      mirodenafil 100mg for three times, respectively and the pharmacokinetic interaction was&#xD;
      compared between the two drugs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy male volunteers were randomized into one group among 6 sequential groups and were&#xD;
      administered alone or in combination with dapoxetine 30mg mirodenafil 100mg in each period.&#xD;
      Bloods were obtained at each time for pharmacokinetic analysis. Safety evaluation was also&#xD;
      done during entire study period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>predose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours post-dose</time_frame>
    <description>Cmax of dapoxetine and mirodenafil</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Curve (AUC)</measure>
    <time_frame>predose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours post-dose</time_frame>
    <description>AUC of dapoxetine and mirodenafil</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>predose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>predose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>predose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F</measure>
    <time_frame>predose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse events</measure>
    <time_frame>During 22 days from first administration of period 1</time_frame>
    <description>Incidence rate of Adverse events</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Drug Interaction Potentiation</condition>
  <arm_group>
    <arm_group_label>M→D→D+M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirodenafil(M) in period 1, Dapoxetine(D) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M→D+M→D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirodenafil(M) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Dapoxetine(D) in period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D→M→D+M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapoxetine(D) in period 1, Mirodenafil(M) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D→D+M→M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapoxetine(D) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Mirodenafil(M) in period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D+M→M→D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapoxetine+Mirodenafil(D+M) in period 1, Mirodenafil(M) in period 2, Dapoxetine(D) in period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D+M→D→M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapoxetine+Mirodenafil(D+M) in period 1, Dapoxetine(D) in period 2, Mirodenafil(M) in period 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapoxetine 30mg</intervention_name>
    <description>Tablet, Orally administered</description>
    <arm_group_label>D+M→D→M</arm_group_label>
    <arm_group_label>D+M→M→D</arm_group_label>
    <arm_group_label>D→D+M→M</arm_group_label>
    <arm_group_label>D→M→D+M</arm_group_label>
    <arm_group_label>M→D+M→D</arm_group_label>
    <arm_group_label>M→D→D+M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirodenafil 100mg</intervention_name>
    <description>Table, Orally administered</description>
    <arm_group_label>D+M→D→M</arm_group_label>
    <arm_group_label>D+M→M→D</arm_group_label>
    <arm_group_label>D→D+M→M</arm_group_label>
    <arm_group_label>D→M→D+M</arm_group_label>
    <arm_group_label>M→D+M→D</arm_group_label>
    <arm_group_label>M→D→D+M</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male adults aged between 19 and 55&#xD;
&#xD;
          -  Body mass index (BMI) in the range of 19 to 27 kg/m2&#xD;
&#xD;
          -  Understand the requirements of the study and voluntarily consent to participate in the&#xD;
             study&#xD;
&#xD;
          -  Available for the entire study period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a history such as liver diseases, kidneys, digestive system, respiratory&#xD;
             system, endocrine system, nervous psychiatric, blood, cancer, cardiovascular diseases&#xD;
&#xD;
          -  Subject with clinically significant vital signs (sitting position blood pressure) (90&#xD;
             mmHg &gt; systolic blood pressure ≥ 140 mmHg, 60 mmHg &gt; diastolic blood pressure ≥ 90&#xD;
             mmHg)&#xD;
&#xD;
          -  History of drug abuse&#xD;
&#xD;
          -  History of caffeine, alcohol, smoking abuse&#xD;
&#xD;
               -  caffeine(coffee,tea,coke)&gt; 4cups/day&#xD;
&#xD;
               -  smoking &gt; 10 cigarettes/day&#xD;
&#xD;
               -  alcohol &gt; 140g/week&#xD;
&#xD;
          -  Consumption of any grapefruit or grapefruit-containing juices over 1 cup a day&#xD;
&#xD;
          -  Previously donate whole blood within 60 days or component blood within 30 days&#xD;
&#xD;
          -  Subject has taken drugs which affects the ADME of investigational products&#xD;
&#xD;
          -  Subject with known for hypersensitivity reactions to mirodenafil/ dapoxetine or other&#xD;
             drugs&#xD;
&#xD;
          -  Inadequate laboratory test result:&#xD;
&#xD;
               -  AST(SGOT) or ALT(SGPT) or total bilirubin &gt; 1.5 x upper limit of normal range&#xD;
&#xD;
          -  Subject considered as unsuitable based on medical judgement by investigators&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min-Gul Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>June 12, 2015</study_first_submitted>
  <study_first_submitted_qc>June 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <last_update_submitted>June 25, 2015</last_update_submitted>
  <last_update_submitted_qc>June 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dapoxetine</keyword>
  <keyword>Mirodenafil</keyword>
  <keyword>DDI study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirodenafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

